stalled for 12 weeks at 10mg and I refuse to panic this time
stalled for 12 weeks at 10mg and I refuse to panic this time. It is the sort of thing everyone half-believes and nobody writes down.
12 weeks and 10mg — those are the numbers, and they are the ones I am willing to defend.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.
Sent a vial to VendorInvestigate out of curiosity. Result was 98.7% against a claimed 98.0%, which is the first independent number I had seen for this compound anywhere.
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
the glucagon component is why the metabolic story reads differently
Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.
comparing reta phase 2 to sema phase 3 is comparing different things
wait for phase 3 before you argue about rankings
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
nothing here is available as a prescription product, so read every thread with that in mind
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
[deleted]
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
the escalation is where most of the reported trouble sits
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
the phase 2 numbers were striking and they were also 48 weeks in a small population
Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
- 1Removed the escalation schedule. There is no published protocol for members…9 comments in this branch · started by u/incretin_ivy